ASCO 2023 | LY3537982: a novel KRAS G12C inhibitor in solid tumors

Joshua Sabari, MD, NYU Langone Health Perlmutter Cancer Center, New York, NY, describes findings from a Phase I trial (NCT04956640) of LY3537982, a novel inhibitor in patients with KRAS G12C-mutant solid tumors. The investigational drug had a safety profile similar to other KRAS G12C inhibitors and in a subset of patients also receiving PD-1 inhibitors, promising responses were additionally reported. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.